Inventiva S.A.

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of an orally administered small molecule for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). https://www.inventivapharma.com

Current securities

1. 6-K filingSep 28, 2026
2. 6-K filingSep 3, 2026
3. 6-K filingSep 1, 2026
4. 6-K/A filingJul 30, 2026
5. 6-K filingJul 9, 2026